AMLX Stock Overview
A clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Amylyx Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.61 |
| 52 Week High | US$7.27 |
| 52 Week Low | US$1.58 |
| Beta | -0.60 |
| 1 Month Change | 26.30% |
| 3 Month Change | 23.26% |
| 1 Year Change | 162.68% |
| 3 Year Change | -45.44% |
| 5 Year Change | n/a |
| Change since IPO | -74.49% |
Recent News & Updates
Can Amylyx Pharmaceuticals (NASDAQ:AMLX) Afford To Invest In Growth?
May 10
Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking
Apr 03Recent updates
Can Amylyx Pharmaceuticals (NASDAQ:AMLX) Afford To Invest In Growth?
May 10Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking
Apr 03
Avexitide Launch In 2027 Will Strengthen Our Pipeline
Apr 01 Strategic developments in the pipeline and collaborations aim to address unmet medical needs and present long-term revenue growth opportunities.Amylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of Recovery
Feb 24Little Excitement Around Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Revenues As Shares Take 26% Pounding
Dec 19Is Amylyx Pharmaceuticals (NASDAQ:AMLX) In A Good Position To Invest In Growth?
Dec 10Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along
Nov 25There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise
Nov 04Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Sep 18Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Jun 25Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop
Apr 25Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Mar 12An ALS Drug Fails Again
Mar 09Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Feb 23Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Feb 23Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper
Nov 10Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Sep 24This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year
May 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Apr 20Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates
Mar 16Shareholder Returns
| AMLX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -13.3% | -6.4% | 0.3% |
| 1Y | 162.7% | -10.0% | 8.0% |
Return vs Industry: AMLX exceeded the US Pharmaceuticals industry which returned -9.8% over the past year.
Return vs Market: AMLX exceeded the US Market which returned 8.1% over the past year.
Price Volatility
| AMLX volatility | |
|---|---|
| AMLX Average Weekly Movement | 12.1% |
| Pharmaceuticals Industry Average Movement | 10.9% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: AMLX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AMLX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 123 | Josh Cohen | amylyx.com |
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases.
Amylyx Pharmaceuticals, Inc. Fundamentals Summary
| AMLX fundamental statistics | |
|---|---|
| Market cap | US$408.46m |
| Earnings (TTM) | -US$218.86m |
| Revenue (TTM) | n/a |
-321.1x
P/S Ratio-1.9x
P/E RatioIs AMLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMLX income statement (TTM) | |
|---|---|
| Revenue | -US$1.27m |
| Cost of Revenue | US$112.31m |
| Gross Profit | -US$113.58m |
| Other Expenses | US$105.27m |
| Earnings | -US$218.86m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.47 |
| Gross Margin | 8,929.48% |
| Net Profit Margin | 17,205.74% |
| Debt/Equity Ratio | 0% |
How did AMLX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 02:39 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amylyx Pharmaceuticals, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Timothy Anderson | BofA Global Research |
| Neena Bitritto-Garg | Citigroup Inc |